ReviewNature reviews. Clinical oncology2024
Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination.
Review in Nature reviews. Clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Burden of HPV Infections and HPV-Related Diseases Among People With HIV: A Systematic Literature Review.Journal of medical virology · 2025Pooled it
- Genotype distribution of human papillomavirus (HPV) types in oral gargle specimens among men living with HIV in Mexico, Brazil, and Puerto Rico: A cross-sectional study.The Journal of infection · 2026Trial
- Immunogenicity and safety of anFrontiers in immunology · 2025Trial
- Psychosocial factors influencing HPV vaccination intention among male college students in Hangzhou city: A cross-sectional study based on an extended theory of planned behavior model.Human vaccines & immunotherapeutics · 2026Article
- Assessing the burden of HPV-associated cancers in Brazil: Hospitalization and mortality trends from 2011 to 2019.Human vaccines & immunotherapeutics · 2026Article
- Clinical research progress and challenges of vaccine for human papillomavirus-associated cancers.Human vaccines & immunotherapeutics · 2026Review
- Geographic and temporal variations in cancer incidence attributable to human papillomavirus infection in China: a population-based study.BMC public health · 2026Article
- The Long-Term Effect of 2 and 3 Doses of Bivalent HPV Vaccination Against HPV Infections: A Comparison Between 2 Observational Cohort Studies.The Journal of infectious diseases · 2026Observational
- Beyond oncogenesis: the unexplored benefits of viruses in cancer immunity.Nature reviews. Cancer · 2026Review
- Wastewater-Based Surveillance of Human Papillomavirus Genotype Diversity.JAMA network open · 2026Article
- Knowledge, Attitudes, and Perceptions of HPV Vaccination for Adolescents with Intellectual Disabilities: A Systematic Review.Vaccines · 2026Review
- Clinical Significance of High-Risk HPV Positivity with Negative Cytology: Can Further Evaluation Be Safely Delayed?Medicina (Kaunas, Lithuania) · 2026Observational
- Clinical Significance of Vulvar Condyloma as a Marker of Concurrent High-Risk Cervical HPV Infection and Abnormal Cervical Cytology.Diagnostics (Basel, Switzerland) · 2026Article
- The Burden and Risk Factors of Head and Neck Cancers in G20 Countries, 1990-2023.International dental journal · 2026Article
- Higher-order multiple primary cancers and persistent cross-site risk across human papillomavirus-related anatomical sites in the United States: a population-based Surveillance, Epidemiology, and End Results study.Preventive medicine reports · 2026Article
- Genetic variation of human papillomavirus type 39 E6 and E7 genes in central China.Virology journal · 2026Article
- Effectiveness of an educational intervention in enhancing parents' knowledge, perception, and acceptability of human papillomavirus vaccine.BMC public health · 2026Article
- Article
- Intra-tumoral microbiota: Key modulators of tumor immunity and therapeutic potential.Genes & diseases · 2026Review
- Covalent inhibitors of human papillomavirus type 16 E6 protein restore p53 function and suppress growth of HPV-driven tumors in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cervical cancer is the first cancer deemed amenable to elimination through prevention, and thus lessons from the epidemiology and prevention of this cancer type can provide information on strategies to manage other cancers. Infection with the human papillomavirus (HPV) causes virtually all cervical cancers, and an important proportion of oropharyngeal, anal and genital cancers. Whereas 20th century prevention efforts were dominated by cytology-based screening, the present and future of HPV-associated cancer prevention relies mostly on HPV vaccination and molecular screening tests. In this Review, we provide an overview of the epidemiology of HPV-associated cancers, their disease burden, how past and contemporary preventive interventions have shaped their incidence and mortality, and the potential for elimination. We particularly focus on the cofactors that could have the greatest effect on prevention efforts, such as parity and human immunodeficiency virus infection, as well as on social determinants of health. Given that the incidence of and mortality from HPV-associated cancers remain strongly associated with the socioeconomic status of individuals and the human development index of countries, elimination efforts are unlikely to succeed unless prevention efforts focus on health equity, with a commitment to both primary and secondary prevention.
Indexed as
Identifiers
38760499What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.